Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2015

Collaboration Agreement [Abstract]

Collaboration revenue with related party

Sanofi collaboration revenue, as detailed below, consisted primarily of reimbursement for research and development expenses that the Company incurred, partly offset by sharing of pre-launch commercialization expenses, in connection with the companies' Discovery and Preclinical Development Agreement ("Antibody Discovery Agreement") and License and Collaboration Agreement (each as amended), collectively referred to as the "Antibody Collaboration".

	Three Months Ended June 30,
Sanofi Collaboration Revenue	2015			2014
Antibody:
Reimbursement of Regeneron research and development expenses	$	211,516		$	137,893
Reimbursement of Regeneron commercialization-related expenses	27,347			4,307
Regeneron's share of losses in connection with commercialization of antibodies	(46,313		)	(4,295		)
Other	2,560			2,560
Total Antibody	195,110			140,465
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	—			(692		)
Reimbursement of Regeneron research and development expenses	—			1,338
Other	—			1,484
Total ZALTRAP	—			2,130
	$	195,110		$	142,595

	Six Months Ended June 30,
Sanofi Collaboration Revenue	2015			2014
Antibody:
Reimbursement of Regeneron research and development expenses	$	380,336		$	264,715
Reimbursement of Regeneron commercialization-related expenses	35,805			5,375
Regeneron's share of losses in connection with commercialization of antibodies	(68,718		)	(4,295		)
Other	5,121			5,121
Total Antibody	352,544			270,916
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	—			(3,904		)
Reimbursement of Regeneron research and development expenses	686			2,430
Other	15,236			3,661
Total ZALTRAP	15,922			2,187
	$	368,466		$	273,103

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Three Months Ended June 30,
Bayer HealthCare Collaboration Revenue	2015		2014
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	106,631	$	66,781
Sales milestones	—		15,000
Cost-sharing of Regeneron EYLEA development expenses	2,464		1,494
Other	16,618		10,813
Total EYLEA	125,713		94,088
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	5,926		626
Other	2,598		2,581
Total PDGFR-beta	8,524		3,207
	$	134,237	$	97,295

	Six Months Ended June 30,
Bayer HealthCare Collaboration Revenue	2015		2014
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	196,057	$	127,940
Sales milestones	15,000		45,000
Cost-sharing of Regeneron EYLEA development expenses	5,121		21,841
Other	29,530		21,745
Total EYLEA	245,708		216,526
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	7,180		1,139
Other	5,195		4,942
Total PDGFR-beta	12,375		6,081
	$	258,083	$	222,607